Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 28:15:1393888.
doi: 10.3389/fneur.2024.1393888. eCollection 2024.

No genetic link between Parkinson's disease and SARS-CoV-2 infection: a two-sample Mendelian randomization study

Xiaohua Hu #  1 , Yutong Li #  2 , Hua Qu  3   4 , Chunying He  1 , Zhiyan Chen  2 , Min Zhan  4 , Yida Du  2 , Huan Wang  1 , Wenjie Chen  5 , Linjuan Sun  4 , Xia Ning  4
Affiliations

No genetic link between Parkinson's disease and SARS-CoV-2 infection: a two-sample Mendelian randomization study

Xiaohua Hu et al. Front Neurol. .

Abstract

Objective: Existing literature has not clearly elucidated whether SARS-CoV-2 infection increases the incidence of Parkinson's disease or if Parkinson's disease patients are more susceptible to the effects of SARS-CoV-2 infection. To clarify the issue, this study employs a genetic epidemiological approach to investigate the association.

Methods: This study utilizes a two-sample Mendelian randomization analysis. The primary analysis employs the inverse variance-weighted (IVW) method, supplemented by secondary analyses including MR-Egger regression, weighted median, IVW radial method, and weighted mode, to evaluate the bidirectional causal relationship between Parkinson's disease and SARS-CoV-2 infection.

Results: IVW results showed no genetic causality between SARS-CoV-2 susceptibility, hospitalization rate and severity and Parkinson's disease. (IVW method: p = 0.408 OR = 1.10 95% CI: 0.87 ~ 1.39; p = 0.744 OR = 1.11 95% CI: 0.94 ~ 1.09; p = 0.436 OR = 1.05 95% CI: 0.93 ~ 1.17). Parkinson's disease was not genetically associated with susceptibility to new crown infections, hospitalization rates, and severity (IVW method: p = 0.173 OR = 1.01 95% CI: 0.99 ~ 1.03; p = 0.109 OR = 1.05 95% CI: 0.99 ~ 1.12; p = 0.209 OR = 1.03 95% CI: 0.99 ~ 1.07). MR-Egger regression, weighted median, IVW radial method, and weighted mode results are consistent with the results of the IVW method.

Conclusion: This study does not support a genetic link between Parkinson's disease and SARS-CoV-2 infection, and the association observed in previous cohort studies and observational studies may be due to other confounding factors.

Keywords: Mendelian randomization study; Parkinson’s disease; SARS-CoV-2; genetic link; infection.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
MR estimates of genetically predicted susceptibility, hospitalization, and severity of COVID-19 on the risk of Parkinson’s disease. The inverse variance weighted method is considered the main method. MR, Mendelian randomization; SNP, Single nucleotide polymorphism; P, p-value; OR, odds ratio; CI, Confidence interval.
Figure 2
Figure 2
MR estimates of genetically predicted risk of Parkinson’s disease on susceptibility, hospitalization, and severity of COVID-19. The inverse variance weighted method is considered the main method. MR, Mendelian randomization; SNP, Single nucleotide polymorphism; P, p-value; OR, odds ratio; CI, Confidence interval.
Figure 3
Figure 3
Results of MR leave-one-out sensitivity analysis. 3-1MR leave−one−out sensitivity analysis for ‘Parkinson’s disease’ on ‘SARS-CoV-2 infection’; 3–2 MR leave−one−out sensitivity analysis for ‘SARS-CoV-2 infection’ on ‘Parkinson’s disease’; 3-3MR leave−one−out sensitivity analysis for ‘Parkinson’s disease’ on ‘Hospitalized COVID-19’; 3-4MR leave−one−out sensitivity analysis for ‘Severe COVID-19’ on ‘Parkinson’s disease’; 3–5 MR leave−one−out sensitivity analysis for ‘Severe COVID-19’ on ‘Parkinson’s disease’; 3–6 MR leave−one−out sensitivity analysis for ‘Parkinson’s disease’ on ‘Severe COVID-19’ MR, Mendelian randomization.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Achbani A, Sine H, Naciri A, Baba MA, Kharbach A, Bouchriti Y, et al. . Can the 2019 novel coronavirus cause Parkinson's disease? Mov Disord. (2020) 35:1102–3. doi: 10.1002/mds.28118, PMID: - DOI - PMC - PubMed
    1. McAlpine LS, Fesharaki-Zadeh A, Spudich S. Coronavirus disease 2019 and neurodegenerative disease: what will the future bring? Curr Opin Psychiatry. (2021) 34:177–85. doi: 10.1097/YCO.0000000000000688, PMID: - DOI - PMC - PubMed
    1. Fu YW, Xu HS, Liu SJ. COVID-19 and neurodegenerative diseases. Eur Rev Med Pharmacol Sci. (2022) 26:4535–44. doi: 10.26355/eurrev_202206_29093, PMID: - DOI - PubMed
    1. Baranova A, Cao H, Zhang F. Causal effect of COVID-19 on Alzheimer's disease: a Mendelian randomization study. J Med Virol. (2023) 95:e28107. doi: 10.1002/jmv.28107, PMID: - DOI - PMC - PubMed
    1. Cartella SM, Terranova C, Rizzo V, Quartarone A, Girlanda P. Covid-19 and Parkinson's disease: an overview. J Neurol. (2021) 268:4415–21. doi: 10.1007/s00415-021-10721-4, PMID: - DOI - PMC - PubMed